Sept. 2020
`
`Peter M. Tessier
`Albert M. Mattocks Professor
`Departments of Pharmaceutical Sciences, Chemical Engineering and Biomedical Engineering
`Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109
`734.763.1486, ptessier@umich.edu, tessier.lab.medicine.umich.edu
`
`EDUCATION
`2003
`
`1998
`
` University of Delaware
`
`
`Ph.D., Chemical Engineering
`Dissertation: “Fundamentals and applications of nanoparticle interactions and self-
`assembly”
`Advisors: Abraham M. Lenhoff and Stanley I. Sandler
`B.S., Chemical Engineering
`Co-Valedictorian
`
`University of Maine
`
`2016-2017
`
`2014-2016
`
`2014-2015
`
`PROFESSIONAL EXPERIENCE
`Albert M. Mattocks (Endowed) Professor
`2017-present
`University of Michigan, Departments of Pharmaceutical Sciences, Chemical
`Engineering and Biomedical Engineering, Biointerfaces Institute
`Richard Baruch M.D. Career Development (Endowed) Professor
`Rensselaer Polytechnic Institute, Department of Chemical & Biological Engineering,
`Center for Biotechnology & Interdisciplinary Studies
`Richard Baruch M.D. Career Development (Endowed) Associate Professor
`Rensselaer Polytechnic Institute, Department of Chemical & Biological Engineering,
`Center for Biotechnology & Interdisciplinary Studies
`Alexander von Humboldt Fellow
`Max Planck Institute for Biochemistry (Martinsried, Germany)
`Host: F. Ulrich Hartl
`Associate Professor
`Rensselaer Polytechnic Institute, Department of Chemical & Biological Engineering,
`Center for Biotechnology & Interdisciplinary Studies
`*granted early tenure (December 2012, promotion effective July 2013)
`Assistant Professor
`Rensselaer Polytechnic Institute, Department of Chemical & Biological Engineering,
`Center for Biotechnology & Interdisciplinary Studies
`American Cancer Society Postdoctoral Fellow
`Whitehead Institute for Biomedical Research (MIT)
`Advisor: Susan Lindquist
`
`2013-2016
`
`2007-2013
`
`2003-2007
`
`ACADEMIC HONORS
`2018
`2016
`2015
`
`2015
`
`2014
`
`Fellow, American Institute for Medical and Biological Engineering
`Young Investigator Award, Biochemical Engineering Journal (Dublin, Ireland)
`Invited participant, USA National Academy of Engineering Frontiers of Engineering
`Symposium
`Young Investigator Award, Division of Biochemical Technology, American
`Chemical Society
`Young Scientist Award, World Economic Forum (Tianjin, China)
`
`Novo Nordisk Ex. 2026, P. 1
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`2014-2015 Alexander von Humboldt Fellowship for Experienced Researchers
`2010-2015 National Science Foundation CAREER Award
`2010-2014
`Pew Scholar Award in Biomedical Sciences
`2014
`Rensselaer Dept. of Chemical & Biological Engineering Teaching Award
`2013
`Rensselaer School of Engineering Teaching Excellence Award
`2012
`Rensselaer Early Career Award
`2012
`Rensselaer School of Engineering Research Excellence Award
`2012
`Allan P. Colburn Lectureship, Univ. of Delaware
`2004-2007 American Cancer Society Postdoctoral Fellowship
`2004
`National Institutes of Health Postdoctoral Fellowship (declined)
`2002
`W.H. Peterson Award, Best Student Presentation (BIOT), ACS National Meeting
`2002
`First Place, Colorado Protein Stability Conference Poster Session
`2001
`Teaching Fellow, Dept. of Chemical Eng., Univ. of Delaware
`2001
`Pigford Teaching Assistant Award, Dept. of Chemical Eng., Univ. of Delaware
`2000
`Semi-Finalist, Discover Magazine Award for Technological Innovation
`1999-2002 NASA Graduate Fellowship
`1998
`Co-Valedictorian, Univ. of Maine
`
`PATENTS
`Lindquist S.L., Krishnan R., Tessier P.M., “Devices from prion-like proteins”, US Patent 11/916,983
`(2009).
`
`BOOK CHAPTERS
`Tessier P.M., Lindquist S.L., “Unraveling molecular mechanisms and structures of self-perpetuating
`prions”, in Protein Misfolding Diseases: Current and Emerging Principles and Therapies, John Wiley
`& Sons. Dobson, C.M., Kelly, J.W. and Ramirez-Alvarado, M. Eds., (2010).
`
`JOURNAL PUBLICATIONS [64 published papers or papers in press, *=corresponding author, †=undergraduate
`student, [ ] = number of citations as of 9/2020, 4472 citations total (Google Scholar), average of 70 citations per paper, h-
`index=32 (Google Scholar)]
`1. Sawant, M.S., Streu, C.N., Wu, L., Tessier, P.M.,*, “Toward drug-like multispecific antibodies by
`design”, in review (2020).
`2. Desai, A.A., Smith, M.D., Zheng, Y., Makowski, E.K., Gerson, J.E., Ionescu, E., Starr, C.G.,
`Paulson, H.L., Tessier, P.M.,* “Rational affinity maturation of anti-amyloid antibodies with high
`conformational and sequence specificity”, in review (2020).
`3. Lou, W., Stimple, S.D., Desai, A.A., Makowski, E.K., Kalyoncu, S., Mogensen, J.E., Spang, L.T.,
`Asgreen, D.J., Staby, A., Duus, K., Amstrup, J., Tessier, P.M.,* “Directed evolution of
`conformation-specific antibodies for sensitive detection of polypeptide aggregates in therapeutic
`drug formulations”, in review (2020).
`4. Zhang, Y., Wu, L., Gupta, P., Desai, A.A., Smith, M.D., Rabia, L.A., Ludwig, S.D.,† Tessier,
`P.M.,* “Physicochemical rules for identifying monoclonal antibodies with drug-like specificity”,
`Mol Pharm, 17, 7 (2020).
`5. Alam, M.E., Slaney, T.R., Wu, L., Das, T.K., Kar, S., Barnett, G.V., Leone, A., Tessier, P.M.,*
`“Unique impacts of methionine oxidation, tryptophan oxidation and asparagine deamidation on
`antibody stability and aggregation”, J Pharm Sci, 109, 656 (2020). [4]
`6. Stimple, S.D., Smith, M.S, Tessier, P.M.,* “Directed evolution methods for overcoming trade-offs
`between protein activity and stability”, AIChE J, 66, e16814 (2020).† [4]
`†Special Issue in honor of Frances Arnold’s Nobel Prize
`7. Lee, C.-H., Kang, T.H., Godon, O., Watanabe, M., Delidakis, G., Gillis, C.M., Sterlin, D., Hardy,
`D., Cogné, M., Macdonald, L.E., Murphy, A.J., Tu, N., Lee, J., McDaniel, J.R., Makowski, E.K.,
`
`Novo Nordisk Ex. 2026, P. 2
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`Tessier, P.M., Meyer, A.S., Bruhns, P.,* Georgiou, G.,* “An engineered, pH-toggle switch, human
`Fc domain for ultra-long circulation persistence”, Nat. Commun., 10, 5031 (2019). [5]
`8. Stimple, S.D., Kalyoncu, S., Desai, A.D., Mogensen, J.E., Spang, L.T., Asgreen, D.J., Staby, A.,
`Tessier, P.M.,* “Sensitive detection of glucagon aggregation using amyloid fibril-specific
`antibodies”, Biotech Bioeng, 116, 1868 (2019). [1]
`9. Julian, M.C., Rabia, L.A., Desai, A.A., Arsiwala, A., Gerson, J.E., Paulson, H.L., Kane, R.S.,
`Tessier, P.M.,* “Nature-inspired design and evolution of anti-amyloid antibodies”, J Biol Chem,
`294, 8438 (2019). [3]
`10. Alam, M.E., Barnett, G.V., Slaney, T.R., Starr, C.G., Das, T.K., Tessier, P.M.,* “Deamidation can
`compromise antibody colloidal stability and enhance aggregation in a pH-dependent manner”, Mol
`Pharm, 16, 1939 (2019). [5]
`11. Starr, C.G., Tessier, P.M.,* “Selecting and engineering monoclonal antibodies with drug-like
`specificity”, Current Opin Biotech, 60, 119 (2019). [8]
`12. Rabia, L.A. Zhang, Y., Ludwig, S.D., Julian, M.C., Tessier, P.M.,* “Net charge of the
`complementarity-determining regions is a key predictor of antibody specificity”, Protein Eng Des
`Sel, 31, 409 (2018). [14]
`13. Rabia, L.A., Desai, A.A., Jhajj, H.S., Tessier, P.M.,* “Understanding and overcoming trade-offs
`between antibody affinity, specificity, stability and solubility”, Biochem. Eng. J., 137, 365 (2018).
`[22]
`14. Alam, M.E., Geng, S.B., Bender, C., Ludwig,† S.D., Linden, L., Hoet, R., Tessier, P.M.,*
`“Biophysical and sequence-based methods for identifying monovalent and bivalent antibodies with
`high colloidal stability”, Mol Pharm, 15, 150 (2018). [11]
`15. Tiller, K.E., Li, L., Kumar, S., Julian, M.C., Garde, S., Tessier, P.M.,* “Arginine mutations in
`antibody complementarity-determining regions display context-dependent affinity/specificity trade-
`offs”, J Biol Chem, 292, 16638 (2017). [21]
`16. Tiller, K.E., Chowdhury, R., Li, T., Ludwig, S.,† Sen, S.,† Maranas, C., Tessier, P.M.,* “Facile
`affinity maturation of antibody variable domains using natural diversity mutagenesis”, Front
`Immunol, 8, 986 (2017). [22]
`17. Julian, M.C., Li, L., Garde, S., Wilen, R.,† Tessier, P.M.,* “Efficient affinity maturation of antibody
`variable domains requires co-selection of compensatory mutations to maintain thermodynamic
`stability”, Sci Rep, 7, 45259 (2017). [42]
`18. Zhao, J., Huvent, I., Lippens, G., Eliezer, D., Zhang, A., Li, Q., Tessier, P.M., Linhardt, R.J.,
`Zhang, F., Wang, C.,* “Glycan determinants of heparin-tau interaction," Biophys J, 112, 921
`(2017). [30]
`19. Nilvebrant, J.,* Tessier, P.M., Sidhu, S.S., “Engineered autonomous human variable domains”,
`Curr Pharm Des, 22, 1 (2016). [15]
`20. Geng, S.B., Wu, J., Alam, M.E., Schultz, J.S., Dickinson, C.D., Seminar, C.R.,† Tessier, P.M.,*
`“Facile preparation of stable antibody-gold conjugates and application to affinity-capture self-
`interaction nanoparticle spectroscopy”, Bioconjug Chem, 27, 2287 (2016). [11]
`21. Geng, S.B., Wittekind, M., Vigil, A. Tessier, P.M.,* “Measurements of monoclonal antibody self-
`association are correlated with complex biophysical properties”, Mol Pharm, 13, 1636 (2016). [18]
`22. Osborne, D.M., Fitzgerald, D.P., O'Leary, K.E., Anderson, B.M., Lee, C.C., Tessier, P.M., McNay,
`E.C.,* “Intrahippocampal administration of a domain antibody that binds aggregated amyloid-β
`reverses cognitive deficits produced by diet-induced obesity”, Biochim Biophys Acta, 1860, 1291
`(2016). [9]
`23. Lee, C.C., Julian, M.C., Tiller, K.E., Meng, F., DuConge, S.E.,† Akter, R., Raleigh, D.P., Tessier,
`P.M.,* “Design and optimization of anti-amyloid domain antibodies specific for Ab and IAPP”, J
`Biol Chem, 291, 2858 (2016). [31]
`24. Tiller, K.E., Tessier, P.M.,* “Advances in antibody design”, Ann Rev Biomed Eng, 17, 191 (2015).
`[99]
`
`Novo Nordisk Ex. 2026, P. 3
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`25. Julian, M.C., Lee, C.L, Tiller, K.E., Rabia, L.A., Day, E.K.,† Schick III, A.J.,† Tessier, P.M.,* “Co-
`evolution of affinity and stability of grafted amyloid-motif domain antibodies”, Protein Eng Des
`Sel, 28, 339 (2015). [20]
`26. Wu, J, Schultz, J.S., Weldon, C.L., Sule, S.V., Chai, Q., Dickinson, C.D.,* Tessier, P.M.,*
`“Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction
`nanoparticle spectroscopy”, Protein Eng Des Sel, 28, 403 (2015). [17]
`27. McBride, S.A., Tilger, C.F., Sanford, S.P., Tessier, P.M., Hirsa, A.H.,* “Comparison of human and
`bovine insulin amyloidogenesis under uniform shear”, J Phys Chem B, 119, 10426 (2015). [15]
`28. Estep, P., Caffry, I., Yu, Y., Sun, T., Cao, Y., Leanaugh, H., Jain, T., Vásquez, M., Tessier, P.M.,
`Xu, Y.,* “An alternative assay to hydrophobic interaction chromatography for high-throughput
`characterization of monoclonal antibodies”, mAbs, 4, 553 (2015). [24]
`29. Li, X., Geng, S.B., Chiu, M.L., Saro, D., Tessier, P.M.,* “High-throughput assay for measuring
`monoclonal antibody self-association and aggregation in serum”, Bioconjug Chem, 26, 520 (2015).
`[9]
`30. Geng, S.B., Cheung, J.K., Narasimhan, C., Shameem, M., Tessier, P.M.,* “Improving monoclonal
`antibody selection and engineering using measurements of colloidal protein interactions”, J Pharm
`Sci, 103, 3356 (2014). [44]
`31. Jayaraman, J., Wu, J., Brunelle,† M.C., Cruz, A.M., Goldberg, D.S., Lobo, B., Shah, A., Tessier,
`P.M.,* “Plasmonic measurements of monoclonal antibody self-association using self-interaction
`nanoparticle spectroscopy”, Biotech Bioeng, 11, 1513 (2014). [27]
`32. Tessier, P.M.,* Wu, J., Dickinson, C.G., “Emerging methods for identifying monoclonal antibodies
`with low propensity to self-associate during the early discovery process”, Expert Opin Drug Deliv,
`11, 461 (2014). [22]
`33. Perchiacca, J.M., Lee, C.C, Tessier, P.M.,* “Optimal charged mutations in the complementarity-
`determining regions that prevent domain antibody aggregation are dependent on the antibody
`scaffold”, Protein Eng Des Sel, 27, 29 (2014). [58]
`34. Liu, Y., Caffry, I., Wu, J., Geng, S.B., Jain, T., Sun, T., Reid, F., Cao, Y., Estep, P., Yu, Y.,
`Vásquez, M., Tessier, P.M., Xu, Y.,* “High-throughput screening for developability during early-
`stage antibody discovery using self-interaction nanoparticle spectroscopy”, mAbs, 6, 483 (2014).
`[56]
`35. Li, X., Zhang, X., Ladiwala, A.R.A, Du, D., Yadav, J.K., Tessier, P.M., Wright, P.E., Kelly, J.W.,
`Buxbaum, J.N.,* “Mechanisms of transthyretin inhibition of Ab aggregation in vitro”, J Neurosci,
`33, 19423 (2013). [85]
`36. Andersson, E.K., Bengtsson, C., Evans, M.L., Chorell, E., Sellstedt, M., Lindgren, A.E.G.,
`Hufnagel, D.A., Bhattacharya, M., Tessier, P.M., Wittung-Stafshede, P., Almqvist, F.,* Chapman,
`M.R.,* “Modulation of curli assembly and pellicle biofilm formation by chemical and protein
`chaperones”, Chem Biol, 20, 1245 (2013). [52]
`37. Lee, C., Perchiacca, J.M., Tessier, P.M.,* “Toward aggregation-resistant antibodies by design”,
`Trends Biotechnol, 31, 612 (2013). [79]
`38. Tiller, K.E., Tessier, P.M.,* “Lifting the veil on amyloid drug design”, eLife, 2, e00857 (2013). [4]
`39. Sule, S.V., Dickinson, C.G., Lu, J., Chow, C.-K., Tessier, P.M.,* “Rapid analysis of antibody self-
`association in complex mixtures using immunogold conjugates”, Mol Pharm, 10, 1322 (2013). [41]
`40. Ladiwala, A.R.A., Bhattacharya, M., Perchiacca, J.M., Cao, P., Raleigh, D.P., Abedini, A., Schmidt,
`A.M., Varkey, J., Langen, R., Tessier, P.M.,* “Rational design of potent domain antibody inhibitors
`of amyloid fibril assembly”, P Natl Acad Sci U S A, 109, 19965 (2012). [77]
`41. Perchiacca, J.M., Ladiwala, A.R.A., Bhattacharya, M., Tessier, P.M.,* “Aggregation-resistant
`domain antibodies engineered with charged mutations near the edges of the complementarity-
`determining regions”, Protein Eng Des Sel, 12, 591 (2012). [101]
`
`Novo Nordisk Ex. 2026, P. 4
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`42. Ladiwala, A.R, Litt, J., Kane, R.S., Aucoin, D.S., Smith, S.O., Ranjan, S, Davis, J., Van Nostrand,
`W.E., Tessier, P.M.,* “Conformational differences between two amyloid b oligomers of similar size
`and dissimilar toxicity”, J Biol Chem, 287, 24765 (2012). [162]
`43. Ladiwala, A.R, Perchiacca, J.M., Fishman, Z.S.,† Bhattacharya, M., Domigan, B.,† Dordick, J.S.,
`Tessier, P.M.,* “Polyphenolic disaccharides endow proteins with unusual resistance to
`aggregation”, Biotech Bioeng, 109, 1869 (2012). [11]
`44. Perchiacca, J.M., Tessier, P.M.,* “Engineering aggregation-resistant antibodies”, Ann Rev Chem
`Biomol Eng, 3, 263 (2012). [106]
`45. Sule, S.V., Cheung, J., Antochshuk, V., Bhalla, A., Narasimhan, C., Blaisdell, S., Shameem, M.,
`Tessier, P.M.,* "Solution pH that minimizes self-association of three monoclonal antibodies is
`strongly dependent on ionic strength", Mol Pharm, 9, 744 (2012). [48]
`46. Perchiacca, J.M., Ladiwala, A.R.A, Bhattacharya, M.B., Tessier, P.M.,* "Structure-based design of
`conformation- and sequence-specific antibodies against amyloid b", P Natl Acad Sci U S A, 109, 84
`(2012). [112]
`47. Posada, D., Tessier, P.M., Hirsa, A.H.,* “Removal versus fragmentation of amyloid-forming
`precursors via membrane filtration”, Biotech Bioeng, 109, 840 (2012). [7]
`48. Sule, S.V., Sukumar, M., Weiss, W.F., Marcelino-Cruz, A.M., Sample, T.,† Tessier, P.M.,* "High-
`throughput analysis of concentration-dependent antibody self-association", Biophys J, 101, 1749
`(2011). [45]
`49. Marcelino-Cruz, A.M., Bhattacharya, M., Anselmo, A.,† Tessier, P.M.,* “Site-specific structural
`analysis of a yeast prion strain with species-specific seeding activity”, Prion, 3, 208 (2011). [6]
`50. Ladiwala, A.R, Mora-Pale, M., Lin, J.C., Bale, S.S., Fishman, Z.S.,† Dordick, J.S., Tessier, P.M.,*
`“Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and
`inactivate toxic oligomers of amyloid β”, ChemBioChem, 12, 1749 (2011). [52]
`51. Perchiacca, J.M., Bhattacharya, M., Tessier, P.M.,* “Mutational analysis of domain antibodies
`reveals aggregation hotspots within and near the complementarity determining regions”, Proteins,
`79, 2637 (2011). [93]
`52. Ladiwala, A.R, Dordick, J.S., Tessier, P.M.,* “Aromatic small molecules remodel toxic soluble
`oligomers of amyloid Ab through three unique pathways”, J Biol Chem, 286, 3209 (2011). [160]
`53. Ladiwala, A.R, Lin, J.C., Bale, S.S., Marcelino-Cruz, A.M., Bhattacharya, M., Dordick, J.S.,
`Tessier, P.M.,* “Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Ab into
`off-pathway conformers”, J Biol Chem, 285, 24228 (2010). [265]
`54. Tessier, P.M.,* Lindquist, S.,* “Unraveling infectious structures, strain variants and species barriers
`for the yeast prion [PSI+]”, Nature Struct Mol Biol, 16, 598 (2009). [88]
`55. Bengali, A.N., Tessier, P.M.,* “Biospecific immobilization of proteins for rapid analysis of weak
`protein interactions using self-interaction nanoparticle spectroscopy”, Biotechnol Bioeng, 104, 240
`(2009). [12]
`56. Tessier, P.M.,* Jinkoji, J., Cheng, Y.C., Prentice, J.L., Lenhoff, A.M., “Self-interaction nanoparticle
`spectroscopy: A nanoparticle-based protein interaction assay”, J Am Chem Soc, 130, 3106 (2008).
`[62]
`57. Tessier P.M., Lindquist S.,* “Prion recognition elements govern nucleation, strain specificity and
`species barriers”, Nature, 447, 557 (2007).† [144]
`†See accompanying commentaries in Nature, 447, 541(2007), Nat Methods, 4, 538 (2007) & J
`Cell Biol, 177, 747 (2007).
`58. Tessier, P.M., Sandler, S.I., Lenhoff, A.M.,* “Direct measurement of protein osmotic second virial
`cross coefficients by cross-interaction chromatography”, Protein Sci, 13, 1379 (2004). [69]
`59. Tessier, P.M., Johnson, H.R., Pazhianur, R., Berger, B.W., Prentice, J.L., Bahnson, B.J., Sandler,
`S.I., Lenhoff, A.M.,* “Predictive crystallization of ribonuclease A via rapid screening of osmotic
`second virial coefficients,” Proteins, 50, 303 (2003). [86]
`
`Novo Nordisk Ex. 2026, P. 5
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`60. Tessier, P.M., Lenhoff, A.M.,* “Measurement of protein self-association as a guide to
`crystallization,” Curr Opin Biotechnol, 14, 512 (2003). [90]
`61. Tessier, P.M., Verruto, V.J., Sandler, S.I., Lenhoff, A.M.,* “Correlation of diafiltration sieving
`behavior of lysozyme-BSA mixtures with osmotic second virial cross coefficients”, Biotechnol
`Bioeng, 87, 303 (2003). [25]
`62. Tessier, P.M., Lenhoff, A.M.,* Sandler, S.I., “Rapid measurement of protein osmotic second virial
`coefficients by self-interaction chromatography,” Biophys J, 82, 1620 (2002). [218]
`63. Tessier, P.M., Vandrey, S.D., Berger, B.W., Sandler, S.I., Lenhoff, A.M.,* “Self-interaction
`chromatography: A novel screening method for rational protein crystallization,” Acta Cryst D, 58,
`1531 (2002). [95]
`64. Tessier P.M., Christesen S.D., Ong K.K., Clemente E.M., Lenhoff A.M., Kaler E.W., Velev O.D.,*
`“On-line spectroscopic characterization of sodium cyanide with nanostructured gold SERS
`substrates,” Appl Spectrosc, 56, 1524 (2002). [60]
`65. Tessier P.M., Velev O.D.,* Kalambur A.T., Lenhoff A.M., Rabolt J.F., Kaler E.W., “Structured
`metallic films for optical and spectroscopic applications via colloidal crystal templating,” Adv
`Mater, 13, 396 (2001). [270]
`66. Tessier P.M., Velev O.D.,* Kalambur A.T., Rabolt J.F., Lenhoff A.M., Kaler E.W., “Assembly of
`gold nanostructured films templated by colloidal crystals and use in surface-enhanced Raman
`spectroscopy,” J Am Chem Soc, 122, 9554 (2000). [427]
`67. Velev O.D.,* Tessier P.M., Lenhoff A.M., Kaler E.W., “A class of porous metallic nanostructures,”
`Nature, 401, 548 (1999). [617]
`INVITED SEMINARS (102 since 2007)
`2020
`Johns Hopkins University, Dept. of Chemical & Biomolecular Eng. (TBD)
`Michigan State University, Dept. of Chemical Engineering & Materials Science (Sept 3)
`American Association of Pharmaceutical Scientists (AAPS) Webinar (Aug 13)
`Patheon (ThermoFisher), Princeton, NJ (Feb 13)
`McGill University, Depart. of Pharmacology & Therapeutics, Montreal, Canada (Oct 25)
`University of Kansas, Dept. of Pharmaceutical Chemistry (Oct 15)
`Amgen, Thousand Oaks, CA (May 9)
`New York University, Dept. of Chemical & Biomolecular Engineering (Apr 26)
`Pfizer, Cambridge, MA (Feb 28)
`Boehringer Ingelheim, Ridgefield, CT (Dec 7)
`University of Colorado, Boulder (Oct 18)
`Iowa State University, Department of Chemical & Biological Engineering (Sept 6)
`Roche Diagnostics, Penzberg, Germany (Aug 22)
`University of Natural Resources and Life Sciences, Vienna, Austria (Aug 20)
`Bayer HealthCare, Wuppertal, Germany (Aug 15)
`Adimab, Lebanon, NH (Jul 16)
`University of Washington, Dept. of Bioengineering (Apr 19)
`Texas A&M, Department of Biochemistry & Biophysics (Feb 28)
`University of California, Santa Barbara, Dept. of Chemical Engineering (Apr 20)
`Sanofi, Framingham, MA (Apr 11)
`Univ. of Michigan, Dept. of Chemical Engineering (Jan 31)
`Univ. of Michigan, Dept. of Department of Pharmaceutical Sciences (Nov 2)
`Univ. of North Carolina, Charlotte, Dept. of Chemistry (Oct 27)
`Imperial College, Department of Chemical Engineering, London, England (Oct 21)
`Bayer HealthCare, Wuppertal, Germany (Jul 11)
`University of Zurich, Dept. of Biochemistry, Switzerland (Jul 6)
`
`2017
`
`2016
`
`2019
`
`2018
`
`Novo Nordisk Ex. 2026, P. 6
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`2015
`
`2014
`
`
`
`
`
`University of Pennsylvania, Dept. of Chemical & Biomolecular Engineering (Apr 20)
`Genor BioPharma, Shanghai, China (Apr 13)
`Pfizer, Cambridge, MA (Feb 25)
`Regeneron Pharmaceuticals, Tarrytown, NY (Jan 29)
`Brooklyn College, Dept. of Biology (Dec 10)
`DuPont, Palo Alto, CA (Dec 2)
`University of Maryland, Dept. of Bioengineering (Nov 20)
`Boehringer Ingelheim, Ridgeway, CT (Oct 9)
`Amgen, Thousand Oaks, CA (Aug 27)
`Morphosys, Martinsried, Germany (Jul 16)
`Technische Universität München, Freising-Weihenstephan, Germany (Jul 14)
`Technische Universität München, Garching, Germany (Jul 1)
`Novo Nordisk, Måløv, Denmark (Jun 15)
`Ludwig-Maximilians-Universität München, Dept. of Pharmacy, Germany (May 21)
`KULeuven, Department of Cellular and Molecular Medicine, Leuven, Belgium (Apr 29)
`Schrödinger, New York, NY (Jan 15)
`Bristol-Myers Squibb, New Brunswick, NJ (Jan 9)
`Boehringer Ingelheim, Biberach, Germany (Nov 13)
`Max Planck Institute of Biochemistry, Martinsried, Germany (Sept 24)
`University of California, Riverside, Dept of Chemical & Environmental Eng. (Jun 6)
`Johns Hopkins University, Dept. of Chemical & Biomolecular Eng. (Apr 24)
`Roche Diagnostics, Penzberg, Germany (Apr 2)
`Bayer HealthCare, Wuppertal, Germany (Mar 28)
`University of Michigan, Dept of Molecular, Cellular, & Developmental Biology (Mar 21)
`
`GRANTS (40 grants to Tessier lab totaling >$7M since 2008)
`
`AWARDS RECEIVED BY LAB MEMBERS
`Postdoctoral associates
`• NIH F32 Postdoctoral Fellowship, Charles Starr, 2018
`• NIH F32 Postdoctoral Fellowship, John Schardt, 2020
`Graduate students
`• NSF Graduate Fellowship, Kathryn Tiller, 2011
`• NSF Graduate Fellowship, Mark Julian, 2012
`• NSF Graduate Fellowship, Lilia Rabia, 2013
`• W.H. Peterson Award for Best Student Oral Presentation, Division of Biochemical Technology,
`American Chemical Society National Meeting, Joseph Perchiacca, 2013
`• W.H. Peterson Award for Best Student Poster Presentation, Division of Biochemical
`Technology, American Chemical Society National Meeting, Shantanu Sule, 2013
`• NSF Graduate Fellowship, Matthew Smith, 2019
`• NIH Cellular Biotechnology (T32) Training Fellowship, Lina Wu, 2019
`Undergraduate students
`• NSF Graduate Fellowship, Evan Day (to attend UPenn, now at University of Virginia), 2014
`• NSF Graduate Fellowship, Malaney Young (to attend the University of Minnesota), 2017
`• NSF Graduate Fellowship, Daniel Wackelin (to attend CalTech), 2018
`
`
`SYNERGISTIC ACTIVITIES
`
`Novo Nordisk Ex. 2026, P. 7
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`Co-chair, Division of Biochemical Technology Meeting (San Diego), American Chemical Society (Mar
`2016)
`Co-chair, 7th International Conference on Biomolecular Engineering, Society of Biological Engineering
`(Jan 2017)
`Vice-chair, 2nd Gordon Research Conference on Biotherapeutics and Vaccines Development (expected
`2021)
`Co-chair, 3rd Gordon Research Conference on Biotherapeutics and Vaccines Development (expected
`2023)
`Session chair, Frontiers in Engineering, US National Academy of Engineering, Irvine, CA, 2016
`Membership Chair, Division of Biochemical Technology, American Chemical Society, 2009-2013
`Editorial Board Member, Journal of Biological Chemistry, 2013-2018
`Review Editor, Frontiers in Molecular Biosciences, 2014-present
`National Science Foundation Panelist, 2008-present
`National Institutes of Health Panelist, 2015-present
`New Visions Math, Engineering, Science and Technology Instructor (for high school seniors), 2009-
`2013
`
`Novo Nordisk Ex. 2026, P. 8
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`